Takeda completed a $1.2bn investment in Innovent Biologics.

Takeda, a company which focuses on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology, completed a $1.2bn investment in Innovent Biologics, a biopharmaceutical company based in China, focused on developing, manufacturing and commercializing high-quality medicines for various diseases, including oncology and autoimmune disorders. "Our collaboration with Innovent reflects the power of partnerships in oncology. By combining innovative science with global development and commercialization expertise, we can advance more options for patients with the potential to address critical treatment gaps. This agreement reflects our deep commitment to developing medicines that enhance and extend the lives of people living with cancer," Teresa Bitetti, Takeda President, Global Oncology Business Unit.